Drug Profile
Tinlarebant - Belite Bio
Alternative Names: aka LBS-008; BPN-14967; LBS-008Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Columbia University
- Developer Belite Bio
- Class Eye disorder therapies; Fluorinated hydrocarbons; Ketones; Piperidines; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action RBP4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry macular degeneration; Stargardt disease